Daiichi Sankyo set out our 2025 Vision of becoming a “Global Pharma Innovator with Competitive Advantage in Oncology.” The vision for Daiichi Sankyo in 2025 entails the Company having a specialty area centered on oncology as the core business, having enriched regional value products aligned with the regional market, and having innovative products and pipelines changing SOC in each market. At the same time, the Company aims to realize shareholders’ value through highly efficient management.

**2025 Vision**

**Global Pharma Innovator with Competitive Advantage in Oncology**

- To have a specialty area*1 centered on oncology as the core business
- To have enriched regional value products*2 aligned with the regional market
- To have innovative products and pipelines changing standard of care (SOC)*3
- To realize shareholders’ value through highly efficient management

*1 Pharmaceuticals mainly prescribed by hospitals and/or specialists
*2 Products aligned with the regional market
*3 Universally applied best treatment practice in today’s medical science

### Why Oncology?

In recent years, new therapeutic drugs and therapies such as cancer immunotherapy and cell therapy have been developed. However, to overcome cancer, there is still a need for more effective and safer drugs and therapies in areas where unmet medical needs are still high. In fiscal 2019, we anticipate the launch of the first oncology product after integration, and we believe that we will be able to establish a core business for cancer, with the DS-8201 of in-house developed products as the leading source of many promising drugs.

Our group is steadily advancing into our 2025 vision, “Global Pharma Innovator with Competitive Advantage in Oncology.”